-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Esketamine Hydrochloride in Bipolar Disorder (Manic Depression)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Esketamine Hydrochloride in Bipolar Disorder (Manic Depression) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Esketamine Hydrochloride in Bipolar Disorder (Manic Depression) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mosedipimod in Radiation Toxicity (Radiation Sickness, Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CU-06 in Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CU-06 in Stroke report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CU-06 in Stroke Drug Details: CU-06 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CU-06 in Acute Lung Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CU-06 in Acute Lung Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CU-06 in Acute Lung Injury Drug Details: CU-06 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CPL-409116 in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CPL-409116 in Pulmonary Arterial Hypertension report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CPL-409116 in Pulmonary Arterial Hypertension Drug Details: CPL-409116 is under development...
-
Product Insights
Psoriatic Arthritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Psoriatic Arthritis - Drugs In Development, 2023’, provides an overview of the Psoriatic Arthritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Psoriatic Arthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Treatment Resistant Depression – Drugs In Development, 2023
Global Markets Direct’s, ‘Treatment Resistant Depression - Drugs In Development, 2023’, provides an overview of the Treatment Resistant Depression pipeline landscape. The report provides comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Alpha-1 Antitrypsin Deficiency (A1AD) - Drugs In Development, 2023’, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Neuropathy – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuropathy - Drugs In Development, 2023’, provides an overview of the Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Bipolar Disorder (Manic Depression) – Drugs In Development, 2023
Global Markets Direct’s, ‘Bipolar Disorder (Manic Depression) - Drugs In Development, 2023’, provides an overview of the Bipolar Disorder (Manic Depression) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bipolar Disorder (Manic Depression), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...